Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Approval

Cancer Treatment

FDA Approves First Glucocorticoid Receptor Blocker for Platinum-Resistant Ovarian Cancer

The ruling follows phase 3 data showing longer survival with relacorilant plus nab-paclitaxel.

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

FDA Approves Epkinly Monotherapy and Triplet Regimen for Relapsed Follicular Lymphoma

FDA Approves Darzalex Faspro as First Therapy for High-Risk Smoldering Multiple Myeloma